Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | July 09, 2014

Drawing the Line When Evaluating Cost vs. Benefit

A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost-conscience environment of healthcare reform, there needs to be a clear, quantifiable return of investment (ROI). This is especially true for new medical technologies that are competing with a long-established standard of care, where the new technology must show either a cost-benefit over the older technology, or must show a big improvement in patient outcomes to justify the added expense. With a device that shows only an incremental increase in benefit, say a 1-2 percent or less improvement over existing technology, the question may become one of economics rather than device effectiveness.

This is not only a question for physicians, as it applies to vendors developing these products as well. One of the biggest examples of this is the case of drug-eluting stents. During the last decade, key stent vendors were in an arms race to build a better device and capture a large share of the then lucrative coronary stent market. This included extremely expensive, blockbuster clinical trials, massive R&D efforts, and lawsuits and countersuits to try to slow down the competition. However, this came to a halt with the SPIRIT IV trial results in 2010, which proved the Abbott Xience stent was the best in the market for patient outcomes and beat out the long-time market leader, the Boston Scientific Taxus stent.  

However, the victory only just edged out Taxus. Stent thrombosis improvements were measured in fractions of less than 1 percent, and ischemia-driven target-lesion revascularization improvements were less than a 2.6 percentage-point absolute reduction. The data proving that Abbott was the top performer by only a small margin came at a staggering cost of nearly a billion dollars and several years of data collection. Few vendors are willing to shell out that sort of cash today to conduct similar sized trials that will be powered with enough patients to show only small incremental improvements.  

In reality, all the drug-eluting stents on the U.S. market today are good devices and all have similar patient outcomes. This has led to stents becoming commodity items, where lower pricing can often trump slightly better trial data. This is why the Xience stent does not master the entire stent market and why competitors remain in the game. 

I shared some additional thoughts on things to consider when looking at new devices and software in the article The Basics for Evaluating New Technology in the July-August issue of DAIC.

Related Content

Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Cook Medical, Zilver PTX, Japan PMS study, CIRSE 2015, two-year results

Image courtesy of Cook Medical

News | Stents Peripheral| October 01, 2015
Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the...
Stentys, CE Mark for self-apposing stent, lower limb artery disease, below-the-knee arteries, critical limb ischemia, PES BTK-70 trial

Image courtesy of Stentys

News | Stents Peripheral| October 01, 2015
Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries...
raysafe, i2, staff dose monitoring
News | Radiation Dose Management| October 01, 2015
October 1,2015 — The first and only system that delivers real-time X-ray radiation dose monitoring for physicians and
News | Cath Lab| September 29, 2015
The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device...
News | Antiplatelet and Anticoagulation Therapies| September 25, 2015
The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety...
CeloNova BioSciences, Cobra PzF coronary stent system, second randomized trial, COBRA-REDUCE

Cobra PzF coronary stent system image courtesy of CeloNova BioSciences Inc.

News | Stents| September 23, 2015
CeloNova BioSciences Inc. announced that it has received conditional approval to start an investigational device...
Overlay Init